探究化脓性汗腺炎与恶性肿瘤风险之间的关联：一项系统综述。 - Suppr | 超能文献

相似文献

1

Investigating the association between hidradenitis suppurativa and malignancy risks: a systematic review.探究化脓性汗腺炎与恶性肿瘤风险之间的关联：一项系统综述。

Arch Dermatol Res. 2024 Dec 5;317(1):68. doi: 10.1007/s00403-024-03580-2.

2

Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections.阿达木单抗、甲氨蝶呤及皮损内注射糖皮质激素有效维持治疗化脓性汗腺炎伴滑膜炎、痤疮、脓疱病、骨肥厚和骨炎综合征。

SAGE Open Med Case Rep. 2018 Jun 1;6:2050313X18778723. doi: 10.1177/2050313X18778723. eCollection 2018.

3

Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.阿达木单抗生物类似药英利昔单抗治疗化脓性汗腺炎的临床经验。

Dermatol Ther. 2020 Nov;33(6):e14387. doi: 10.1111/dth.14387. Epub 2020 Oct 19.

4

Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience.阿达木单抗治疗化脓性汗腺炎患者的临床及超声特征：一项单中心真实世界研究

Acta Derm Venereol. 2020 Jun 11;100(13):adv00172. doi: 10.2340/00015555-3520.

5

Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.阿达木单抗治疗伴发银屑病和化脓性汗腺炎有效：一组病例报告。

Indian J Dermatol Venereol Leprol. 2021 Mar-Apr;87(2):223-226. doi: 10.4103/ijdvl.IJDVL_455_18.

6

Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting.阿达木单抗联合手术与阿达木单抗单药治疗化脓性汗腺炎的比较：真实世界环境中的一项随机对照试验。

J Am Acad Dermatol. 2023 Oct;89(4):677-684. doi: 10.1016/j.jaad.2023.04.034. Epub 2023 Apr 27.

7

Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。

Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.

8

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?从阿达木单抗原研药转换为生物类似药治疗化脓性汗腺炎：除了成本效益之外还有什么？

Dermatol Ther. 2022 Nov;35(11):e15803. doi: 10.1111/dth.15803. Epub 2022 Sep 14.

9

Factors associated with therapeutic response to adalimumab in hidradenitis suppurativa: evidence from the Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be).化脓性汗腺炎中与阿达木单抗治疗反应相关的因素：来自欧洲化脓性汗腺炎注册中心比利时患者（ERHS-Be）的证据。

Arch Dermatol Res. 2025 Jan 7;317(1):189. doi: 10.1007/s00403-024-03675-w.

10

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn's Disease?化脓性汗腺炎作为克罗恩病患者使用阿达木单抗的一种矛盾的副作用？

Clin Exp Gastroenterol. 2020 Aug 19;13:293-298. doi: 10.2147/CEG.S263685. eCollection 2020.

本文引用的文献

1

Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa.评估化脓性汗腺炎患者的总体和特定癌症风险。

JAMA Dermatol. 2020 Aug 1;156(8):844-853. doi: 10.1001/jamadermatol.2020.1422.

2

Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa.一名接受阿达木单抗治疗化脓性汗腺炎的患者发生转移性鳞状细胞癌。

JAAD Case Rep. 2017 Oct 5;3(6):489-491. doi: 10.1016/j.jdcr.2017.08.017. eCollection 2017 Nov.

3

Mucinous adenocarcinoma in association with hidradenitis suppurativa.